The authors evaluate the effect of various mill types on particle-size distribution, flowability, tabletability, and compactibility. The particle-size distribution of a pharmaceutical granulation is ...
Formulation development can involve several complex technical challenges, but an approach incorporating design of experiments can help address these difficulties. All pharmaceutical drug products are ...
When selecting the appropriate formulation of Livmarli, the patient's weight and ability to swallow tablets should be considered. Livmarli tablets are supplied in 10mg, 15mg, 20mg, and 30mg dosage ...
New formulation provides patients with a simplified dosing experience—reducing pill burden and enhancing ease of administration—while preserving flexible dosing options SAN CARLOS, Calif., June 11, ...
SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved a new ...
Zanubrutinib's new tablet formulation is approved for all five indications, reinforcing its market leadership among BTK inhibitors. The 160 mg tablet simplifies dosing, reducing the daily intake from ...
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed the acalabrutinib 100mg tablets were bioequivalent to the acalabrutinib 100mg capsules. The Food and Drug ...
The European Medicines Agency’s human medicines committee has recommended approval of a new tablet formulation of BeOne Medicines’ targeted blood cancer drug Brukinsa (zanubrutinib). The company ...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized the tablet formulation of LIVMARLI® (maralixibat) for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results